Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Migraine Clear all
Completed Phase 1 Interventional Results available

AMG 334 20160172 Pediatric Migraine PK Study.

NCT03499119
View directory record Official record
Conditions
Migraine
Interventions
AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Little Rock, Arkansas • Englewood, Colorado • Stamford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 28, 2026, 4:57 PM EDT
Withdrawn Phase 2 Interventional

Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients

NCT04466826
View directory record Official record
Conditions
Migraine in Children, Pain, Neuropathic
Interventions
Headache Journal, Sphenopalatine Block, Tx360
Other · Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 28, 2026, 4:57 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

NCT04616326
View directory record Official record
Conditions
Chronic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

NCT04458857
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Little Rock, Arkansas • Banning, California • Loma Linda, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Recruiting Phase 3 Interventional

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

NCT05897320
View directory record Official record
Conditions
Episodic Migraine
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
6 Years to 17 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Stamford, Connecticut • Gulf Breeze, Florida • Hialeah, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Completed Not applicable Interventional

A Study of Family-based Cognitive-behavioral Therapy for Chronic Pediatric Headache and Anxiety

NCT01182051
View directory record Official record
Conditions
Pediatric, Headache, Anxiety
Interventions
CBT or relaxation training
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
7 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Sep 28, 2026, 4:57 PM EDT
Recruiting Phase 3 Interventional

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141
View directory record Official record
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds

NCT02287376
View directory record Official record
Conditions
Migraine
Interventions
Diclofenac Potassium for Oral Solution
Drug
Lead sponsor
Depomed
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Tampa, Florida • Amherst, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 28, 2026, 4:57 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department

NCT03576820
View directory record Official record
Conditions
Migraine
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
10 Years to 20 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 28, 2026, 4:57 PM EDT
Recruiting Not applicable Interventional

Responding With Evidence and Access for Childhood Headaches

NCT05889624
View directory record Official record
Conditions
Headache, Headache Disorders, Headache, Migraine, Migraine, Migraine Disorders, Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions
CBT, Amitriptyline
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Completed Not applicable Interventional

Intervention for Sleep and Pain in Youth: A Randomized Controlled Trial

NCT04936321
View directory record Official record
Conditions
Insomnia, Migraine Disorders, Headache Disorders
Interventions
Internet-delivered CBT for Insomnia, Internet-delivered CBT for Pain Management, Internet-delivered Sleep Education
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 17 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

NCT04396236
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
77
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

NCT05711394
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Placebo-Matching Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Recruiting Phase 3 Interventional

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant, Placebo for Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 17 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
32
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age

NCT04464707
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Little Rock, Arkansas • Banning, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 28, 2026, 4:57 PM EDT
Withdrawn Not applicable Interventional

Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine

NCT00777218
View directory record Official record
Conditions
Migraine
Interventions
propranolol, zonisamide, topiramate
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 28, 2026, 4:57 PM EDT
Completed Not applicable Interventional Results available

Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients

NCT02485418
View directory record Official record
Conditions
Migraine Headache
Interventions
Propofol
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
7 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 28, 2026, 4:57 PM EDT
Recruiting Phase 3 Interventional

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242
View directory record Official record
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Results available

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

NCT03988088
View directory record Official record
Conditions
Migraine
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Newport Beach, California • Stamford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Sep 28, 2026, 4:57 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

NCT05707949
View directory record Official record
Conditions
Migraine Prophylaxis
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
35
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 28, 2026, 4:57 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 28, 2026, 4:57 PM EDT
Withdrawn Phase 4 Interventional

Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department

NCT01534806
View directory record Official record
Conditions
Migraine
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 28, 2026, 4:57 PM EDT
Completed Not applicable Interventional Results available

Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents

NCT01118988
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS), Functional Abdominal Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS), Myofacial Pain, Chronic Daily Headaches, Migraine Headaches, Chronic Pain
Interventions
Mentorship
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 28, 2026, 4:57 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

NCT03836040
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 4:57 PM EDT